SOURCE: Akers Biosciences, Inc.

Akers Biosciences, Inc.

August 18, 2016 07:00 ET

Akers Biosciences Completes Study on First Rapid Breath Test for Oxidative Stress

Test Demonstrates 99.5% Correlation With Reference Laboratory Method

THOROFARE, NJ--(Marketwired - Aug 18, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces the results of a study of the Company's BreathScan OxiCheck™ test ("OxiChek™"), the first disposable breath test to rapidly determine levels of oxidative stress in the body -- an indicator of the overall health and wellbeing of a person.

The study was performed in Philadelphia, PA, under the supervision of Adam C. Sobel M.D., Director, Medical of Akers Bio. The results were highly successful with a correlation between OxiChek™ and the standard reference laboratory blood testing method (TBARS) of 99.5%. The study demonstrated a reproducibility of 100%, meaning the test results from the same lung simulator had zero variation after multiple repeats. The study further demonstrated an intra-subject variation ranging from 1.61% to 14.87%, indicating a narrow variation upon multiple repeat tests by the same human subject.

OxiChek™ is a general wellness product from Akers Wellness™, intended to measure indicators of oxidative stress in exhaled breath. Unlike current laboratory testing methods that test only a few free radicals using an invasive blood draw -- and have a turnaround time of 7 to 10 days -- Akers Bio's rapid OxiChek™ test detects a broad spectrum of free radicals contained in a person's exhaled breath in just a few minutes. 

OxiChek™ works with BreathScan Lync™, the new bluetooth-enabled reading device from Akers Wellness™, to enable users to track their results via a mobile device. It can be used to promote, track and/or encourage choices, such as use of nutritional supplements which, as part of a healthy lifestyle, may help to reduce the risk of certain chronic diseases or conditions. 

Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific Director of Akers Bio, said: "Once again a study has demonstrated an exceptionally high correlation between an Akers Bio rapid breath test and an established reference laboratory blood test. This further underpins the value which we believe lies within our proprietary breath testing technology which we have always believed would very closely mirror blood testing for certain biomarkers.

"We are very excited about these particular study results for OxiChek™. Not only do they demonstrate the effectiveness of our test for oxidative stress, but the comparison to the standard reference laboratory test -- blood vs breath -- is remarkable. Add to this the results of an earlier study that showed a significant correlation between OxiChek™ results and the age of the test subjects, and we believe that we have a powerful tool for the expansive health and wellness and anti-aging industry."

John J. Gormally, Chief Executive Officer of Akers Bio, added: "I am delighted with the outcome of this study. Our work in demonstrating the efficacy of the OxiChek™ test strongly underpins the commercialization strategy for this exciting new product from Akers Bio. We have just begun selling OxiChek™ through our recently appointed distributor Aero-Med, which is targeting the anti-aging, functional and integrative health and wellness treatment practitioner market in the US; and we are also in active discussions with other distribution partners for OxiChek™ with capabilities within other target markets."

BreathScan OxiChek™ and other Akers Bio health and wellness tests do not require US FDA clearance and are being marketed now in the US and other territories covered by the Company's international distribution network.

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Contact Information

  • For more information:

    Akers Biosciences, Inc.
    Raymond F. Akers, Jr. PhD
    Co-founder and Chief Scientific Director
    Tel. +1 856 848 8698

    Taglich Brothers, Inc. (Investor Relations)
    Chris Schreiber
    Tel. +1 917 445 6207
    Email: cs@taglichbrothers.com

    finnCap (UK Nominated Adviser and Broker)
    Adrian Hargrave / Scott Mathieson (Corporate Finance)
    Steve Norcross (Broking)
    Tel. +44 (0)20 7220 0500

    Vigo Communications (Global Public Relations)
    Ben Simons / Fiona Henson
    Tel. +44 (0)20 7830 9700
    Email: akers@vigocomms.com